Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

Data ReadoutpositiveRedemploPositive

AI Analysis

Summary

Arrowhead Pharmaceuticals' gene silencer Redemplo demonstrated positive results in two late-stage trials for triglyceride disease, showing competitiveness with Ionis' similar treatment and potential for expanded patient population.

Clinical Trial Data

Phase

Phase_3

Primary Endpoint

Met

Outcome Details

Late-stage trial data showed Arrowhead's Redemplo cut triglycerides and is competitive with Ionis' product

Importance:7/10

Sentiment:

0.75

gene therapylipid disordertriglycerideslate-stage datacompetitive positioning

Related Companies

$IONS

Read the original article

Published by Endpoints News on July 22, 2026 3:32 PM

Read Original